Found: 7
Select item for more details and to access through your institution.
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 8, p. 805, doi. 10.1001/jamadermatol.2024.1536
- By:
- Publication type:
- Article
695 - Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.069
- By:
- Publication type:
- Article
416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.036
- By:
- Publication type:
- Article
417 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.037
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 8, p. 1, doi. 10.1111/cts.13874
- By:
- Publication type:
- Article
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 7, p. 2991, doi. 10.1007/s12325-024-02810-3
- By:
- Publication type:
- Article
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice